Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Next Previous
X
Search
Trial Profile

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Decitabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 29 Sep 2020 The number of treatment arms has been increased from 2 to 6, by the addition of 2 more arms for Phase 1 and another 2 arms for Phase 2. the primary end-point is changed to measure the maximum tolerated dose of ONLY dasatinib (initially, it was measuring MTD for both Dasatinib and Decitabine).
    • 28 Jul 2020 Status changed from active, no longer recruiting to discontinued per memo from PI/study team
    • 23 Jan 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top